NMRD - Nemaura Medical Inc.
Chart Events
Williams %R
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 6.75 |
| Open | 6.71 |
| Bid | 5.05 x 1400 |
| Ask | 8.50 x 1200 |
| Day's Range | 6.56 - 7.29 |
| 52 Week Range | 2.50 - 14.80 |
| Volume | 35,253 |
| Avg. Volume | 34,143 |
| Market Cap | 150.86M |
| Beta (5Y Monthly) | -0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.21 |
| Earnings Date | Feb 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
Fair Value
Related Research
- Business Wire
Nemaura Medical 2020 Stock Incentive Plan Approved at Annual General Meeting
Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced its 2020 Omnibus Incentive Plan ("Plan") was approved by shareholder vote at the Company’s Annual General Meeting on May 15, 2020. A maximum of 1,000,000 shares of Common Stock have been made available for Awards under the Plan.
- Business Wire
Nemaura reports positive data from early head-to-head comparison with a major incumbent CGM Device
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced positive initial user-volunteer data from its head-to-head comparison with a major incumbent CGM device.
- Business Wire
Nemaura Medical Announces Interview with CEO to Air on May 11
Nemaura Medical Announces Interview with CEO to Air on May 11
- Business Wire
Nemaura Secures $5 Million Loan to Accelerate Commercial Strategy
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), today announced it has secured a 24-month, $5 million non-convertible loan. The loan does not include warrants or other equity securities.
- Business Wire
Nemaura Plans To Launch Body-Worn Continuous Temperature Monitor (CTM) to Track Fever Caused by Viral Infections such as COVID-19
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), announced plans for a new product line by seeking to immediately repurpose sugarBEAT® as a CTM since its inbuilt temperature sensor is capable of continuously tracking body temperature through the skin. Nemaura is considering various options to expedite the launch of a CTM, including potential partnerships and direct to consumer sales.
- GuruFocus.com
Nemaura Medical: The Potential proBEAT Launch Adds Some Steam
The med-tech company is planning to launch a new digital health care subscription service Continue reading...
- Business Wire
Nemaura to Launch New Digital Brand proBEAT™ in the USA, Targeting a Market of Over 100 Million Potential Users With Its Prescription-Free Consumer Wellness Glucose Monitoring Device and Digital Healthcare Subscription Service
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced it is planning to launch a digital healthcare subscription service in the USA under the brand name proBEAT™.
- GuruFocus.com
Nemaura Medical: A Diabetes-Oriented Med-Tech Play
The company's continuous glucose monitor is a potential breakthrough in the diabetes diagnostics space, and also the reason why its stock has gained momentum Continue reading...
- Newsfile
Nemaura Medical Launches Non-Invasive Glucose Monitor in the US
FDA feedback leads to continuous glucose monitor placement into the wellness device category New York, New York--(Newsfile Corp. - March 20, 2020) - Small Caps Daily recently published an article on Nemaura Medical, Inc. (NASDAQ: NMRD), after the Company's latest surge in press coverage, piqued the publication's interest. The media interest is warranted, as it surrounds the preparations for the launch of Nemaura Medical's non-invasive and flexible continuous glucose monitor ("CGM"), sugarBEAT® in the U.S., ...
- Business Wire
Nemaura To Prepare for Launch of sugarBEAT® CGM In the U.S. Following FDA Feedback
Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced it is preparing for the launch of sugarBEAT® in the U.S. under the wellness category following recent feedback from the U.S. Food and Drug Administration (the "FDA"). The Company is prioritizing launch plans in the U.S. and is considering various options to expedite the launch, including potential partnering in continuation of its on-going discussions with multi-national companies.
- Business Wire
Nemaura Medical Enters Into Multiple Verbal Non-Binding Agreements for its sugarBEAT® Platform
Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced it has entered in to multiple verbal non-binding agreements for sugarBEAT® with the aim of securing regional and global partnerships.
- Business Wire
Nemaura Medical Launches sugarBEAT® App on Play Store Ahead of its Planned Commercial Launch of BEAT®diabetes Subscription Service
Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, launched its sugarBEAT® App for Android devices on the Play Store in preparation for the planned launch of the Company’s BEAT®diabetes subscription based service expected for next month.1
- GlobeNewswire
Nemaura Medical Reports Results and Provides Business Update for the Third Quarter Ended December 31, 2019
The Company announced a partnership with the award-winning UK-based company, Changing Health, to bring digital behavior programs to improve the management, reversal and prevention of Type 2 diabetes in multiple territories commencing with the United Kingdom and Ireland. Changing Health is a provider of digital coaching services to the National Health Service England, aimed at the prevention or reversal of Type 2 diabetes.
- GlobeNewswire
Nemaura Provides 2019 Year-End Corporate Update
Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update. The company started the first phase of our commercial launch of sugarBEAT® in the United Kingdom with the first shipments of sugarBEAT® CGM devices to diabetic and pre-diabetic patients from whom positive user feedback has been received.
- GlobeNewswire
Nemaura Medical and Changing Health announce Partnership to provide award-winning Diabetes Behavioral Change services
Loughborough, England, Dec. 17, 2019 -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible.
- GlobeNewswire
Nemaura Medical announces expansion of SugarBEAT® offering with BEAT® Diabetes digital subscription services
Loughborough, England, Dec. 05, 2019 -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a.
- GlobeNewswire
Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract a Wider Universe of Institutional Investors
The reverse split is expected to take effect at the market open on December 5, 2019. In accordance with the reverse split, each stockholder’s percentage ownership interest in Nemaura Medical remains unchanged. Any fractional shares resulting from the reverse stock split were rounded up to the nearest whole share of common stock.
- Benzinga
The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
- GlobeNewswire
Nemaura Medical Reports Results and Provides Business Update for the Second Quarter Ended September 30, 2019
Loughborough, England, Nov. 11, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the second quarter ended September 30, 2019. Dr. Faz Chowdhury, CEO of Nemaura commented, “This has been an exciting period for Nemaura as we officially commenced the commercial rollout plans for SugarBEAT® following our recent CE approval. As the world’s first non-invasive, safe, needle-free CGM, SugarBEAT® is uniquely positioned to target the underserved $80 billion market for Type 2 diabetics and pre-diabetics.
- GlobeNewswire
Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT® and First Patient User Experiences as Presented at EASD Symposia 2019 in Barcelona
Loughborough, England, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided an update regarding the commercial launch of SugarBEAT® and feedback from its first patient user experiences as presented at the recent symposia hosted by Nemaura at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona. Dr. Faz Chowdhury, Chief Executive Officer, discussed key milestones in the development and plans for the commercial rollout program for SugarBEAT® in the UK, Ireland, Germany and other key European markets following its recent CE mark approval in the European Union.
- Simply Wall St.
Is Nemaura Medical (NASDAQ:NMRD) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 2019
Loughborough, England , Sept. 12, 2019 -- Loughborough, England – September 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on.
- GlobeNewswire
Nemaura Medical Reports Quarterly Results for First Quarter Ended June 30, 2019
Loughborough, England, Aug. 09, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the first quarter ended June 30, 2019. The credit facility is at 8% interest, with interest payments due quarterly and principal due in full at maturity in five years. The credit facility has no stock, warrants, or equity related instruments, or other associated expenses. With adequate cash on hand and the credit facility, along with anticipated revenue, Management has instructed Maxim to suspend all ATM activities.
- GlobeNewswire
Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First Phase of Launch
Loughborough, England, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced the first shipments of SugarBEAT® to diabetic and pre-diabetic patients in the United Kingdom. Nemaura Medical will present data from its first users as part of several presentations planned at a symposium being held by the Company at the European Association for the Study of Diabetes (EASD) conference in Barcelona on September 19, 2019.
- GlobeNewswire
Nemaura Medical Inc. Announces $8 million Senior Debt Facility Provided by Existing Investors
Loughborough, England, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced an $8 million (USD) senior credit facility from existing major shareholders, with the first $3.5 million available immediately, to help fund the Company’s European commercial launch plans. The non-dilutive credit facility will carry 8% interest with quarterly payments and the principal due only upon maturity in 5 years. The credit facility has no stock, warrants, or equity related instruments, or other associated expenses. Dr. Faz Chowdhury, CEO of Nemaura, stated, “Nemaura is at an exciting inflection point, having recently received CE Mark approval for SugarBEAT®, the world’s first non-invasive, needle-free, continuous glucose monitor. We recently submitted a De Novo 510(k) medical device application to the U.S. Food and Drug Administration for SugarBEAT®.
